Advanced stent coating for drug delivery and in vivo biocompatibility
Source abstract
Abstract
As an effort to alleviate stent-induced cardiovascular injury including restenosis and thrombosis, advanced drug-eluting stent (ADES) with a bilayer construct composed of a top-coat made of collagen and a base-coat incorporated with N-nitrosomelatonin (NOMela)-loaded PLGA nanoparticles has been developed. NOMela is a hydrophobic prodrug of nitric oxide (NO) that is an endogenous anti-platelet compound. ADES was coated with PLGA nanoparticles via either electrophoretic deposition (EPD) technique or dip-coating technique, and their coating characteristics and efficacies were compared. The drug-loading efficacy and in vitro drug-release profiles from ADES were expressed with various variables including the additives to the collagen layer, the number of layers of the collagen top-coat, the hydrophobicity/hydrophilicity of the loaded drug, the coating technique of nanoparticles, and the concentration of coating emulsions in the EPD method. The morphological status of cross-section and surface of ADES was evaluated by laser scanning confocal microscope and scanning electronic microscope. The real-time release profiles of NO were assessed using the NO-microbiosensor. The anti-platelet activity of ADES was evaluated on the rabbit whole blood using an aggregometer. The intima formation and protein expression in aorta were examined using an in vivo rat model. Both collagen and PLGA used in ADES are biodegradable polymers that fully degrade and consequently produce less inflammation responses. NO released from ADES significantly reduced platelet aggregation in the rabbit blood as compared with those exposed to the control stents. ADES coated with a double layer consisted of collagen and PLGA and containing NOMela was less antigenic at the implanted sites and alleviating intima formation and thrombosis. An external exposure of aorta to NO elicits distinct and specific effects on mitogen-activated protein kinase (MAPK) and Ca2+/calmodulin-dependent protein kinase II (CaMKII) activities which evoke the endoplasmic reticulum (ER) stress response. These findings elucidated that coordinate and reciprocal alterations in the protein kinases followed by the ER stress protein expression are an integral feature of the in-stent-mediated cardiovascular injury.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Coronary Interventions and Diagnostics · Polymer Surface Interaction Studies · Antiplatelet Therapy and Cardiovascular Diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (56)
Show source-provided references
1. Acharya G, Hopkins R, Lee CH (2011) The effects of advanced polymeric matrix on cardiovascular complications. J Biomed Mater Res A 99(3):485–492
2. Acharya G, Lee Y, Lee CH (2012) Optimization of cardiovascular stent against restenosis: factorial design based statistical analysis of polymer coating conditions. PLoS One 7(8):e4310010.1371/journal.pone.0043100 ↗
3. Ajizian SJ, English BK, Meals EA (1999) Specific inhibitors of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways block inducible nitric oxide synthase and tumor necrosis factor accumulation in murine macrophages stimulated with lipopolysaccharide and interferon-gamma. J Infect Dis 179(4):939–944. doi: 10.1086/31465910.1086/314659 ↗
4. Alvin Koh WC, Rahman MA, Choe ES, Lee DK, Shim YB (2008) A cytochrome c modified-conducting polymer microelectrode for monitoring in vivo changes in nitric oxide. Biosens Bioelectron 23(9):1374–1381. doi: 10.1016/j.bios.2007.12.00810.1016/j.bios.2007.12.008 ↗
5. Anderson ME (2005) Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. Pharmacol Ther 106(1):39–55. doi: 10.1016/j.pharmthera.2004.11.00210.1016/j.pharmthera.2004.11.002 ↗
6. Anfossi G, Russo I, Massucco P, Mattiello L, Cavalot F, Balbo A, Trovati M (2002) Adenosine increases human platelet levels of cGMP through nitric oxide: possible role in its antiaggregating effect. Thromb Res 105(1):71–7810.1016/S0049-3848(01)00412-1 ↗
7. Beardmore VA, Hinton HJ, Eftychi C, Apostolaki M, Armaka M, Darragh J, McIlrath J, Carr JM, Armit LJ, Clacher C, Malone L, Kollias G, Arthur JS (2005) Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol 25(23):10454–1046410.1128/MCB.25.23.10454-10464.2005 ↗
8. Calvert PA, Bennett MR (2009) Restenosis revisited. Circ Res 104(7):823–825. doi: 10.1161/CIRCRESAHA.109.19634510.1161/CIRCRESAHA.109.196345 ↗
9. Camenzind E, De Scheerder IK (eds) (2005) Local drug delivery for coronary artery disease: established and emerging applications. Taylor & Francis Group, New York
10. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369(9562):667–67810.1016/S0140-6736(07)60314-6 ↗
11. Dean JL, Brook M, Clark AR, Saklatvala J (1999) p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem 274(1):264–26910.1074/jbc.274.1.264 ↗
12. Dyszkiewicz-Korpanty AM, Frenkel EP, Sarode R (2005) Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods. Clin Appl Thromb Hemost 11(1):25–3510.1177/107602960501100103 ↗
13. Farndale RW, Sixma JJ, Barnes MJ, De Groot PG (2004) The role of collagen in thrombosis and hemostasis. J Thromb Haemost 2:561–57310.1111/j.1538-7836.2004.00665.x ↗
14. Forrester JS, Fishbein M, Helfant R, Fagin J (1991) A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 17(3):758–76910.1016/S0735-1097(10)80196-2 ↗
15. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME (2003) Six- and twelve-month results from a randomized, double-blind trial on a slow-release Paclitaxel-eluting stent for de novo coronary lesions. Circulation 107:38–4210.1161/01.CIR.0000047700.58683.A1 ↗
16. Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P, Fischman D, Goldberg S, Brinker JA, Zeiher AM, Shapiro LM, Willerson J, Davis BR, Ferguson JJ, Popma J, King SB 3rd, Lincoff AM, Tcheng JE, Chan R, Granett JR, Poland M (2002) Results of prevention of restenosis with tranilast and its outcomes (PRESTO) trial. Circulation 106(10):1243–125010.1161/01.CIR.0000028335.31300.DA ↗
17. Ielasi A, Latib A, Colombo A (2011) Current and Future Drug-eluting Coronary Stent Technology. Expert Rev Cardiovasc Ther 9(4):485–50310.1586/erc.11.5 ↗
18. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, Gruetter CA (1981) Mechanism of vascular smooth-muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric-oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 218(3):739–749
19. Indolfi C, Avvedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G, Stabile E, Feliciello A, Mele E, Giuliano P, Condorelli G et al (1995) Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med 1(6):541–54510.1038/nm0695-541 ↗
20. Indolfi C, Cioppa A, Stabile E, Di Lorenzo E, Esposito G, Pisani A, Leccia A, Cavuto L, Stingone AM, Chieffo A, Capozzolo C, Chiariello M (2000) Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 35(1):214–22110.1016/S0735-1097(99)00526-4 ↗
21. Johnson GV, Bailey CD (2003) The p38 MAP kinase signaling pathway in Alzheimer’s disease. Exp Neurol 183(2):263–26810.1016/S0014-4886(03)00268-1 ↗
22. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48(1):193–20210.1016/j.jacc.2006.03.042 ↗
23. Kim SY, Jeoung NH, Oh CJ, Choi YK, Lee HJ, Kim HJ, Kim JY, Hwang JH, Tadi S, Yim YH, Lee KU, Park KG, Huh S, Min KN, Jeong KH, Park MG, Kwak TH, Kweon GR, Inukai K, Shong M, Lee IK (2009) Activation of NAD(P)H:quinone oxidoreductase 1 prevents arterial restenosis by suppressing vascular smooth muscle cell proliferation. Circ Res 104(7):842–850. doi: 10.1161/CIRCRESAHA.108.18983710.1161/CIRCRESAHA.108.189837 ↗
24. Kirsch M, de Groot H (2009) N-nitrosomelatonin: synthesis, chemical properties, potential prodrug. J Pineal Res 46:121–12710.1111/j.1600-079X.2008.00655.x ↗
25. Kluge J, Fusaro F, Mazzotti M, Muhrerb G (2009) Production of PLGA micro- and nanocomposites by supercritical fluid extraction of emulsions: iI Encapsulation of Ketoprofen. J Supercrit Fluids 50:336–34310.1016/j.supflu.2009.05.002 ↗
26. Kunicki TJ (2002) The Influence of Platelet Collagen Receptor Polymorphisms in Hemostasis and Thrombotic Disease. Arterioscler Thromb Vasc Biol 22:14–2010.1161/hq0102.100458 ↗
27. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L (2007) Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356:1009–101910.1056/NEJMoa067722 ↗
28. Lee CH, Singla A, Lee Y (2001) Biomedical application of collagen. Int J Pharm 221(1–2):1–22
29. Lee DK, Koh WC, Shim YB, Shim I, Choe ES (2010) Repeated cocaine administration increases nitric oxide efflux in the rat dorsal striatum. Psychopharmacology 208(2):245–256. doi: 10.1007/s00213-009-1724-z10.1007/s00213-009-1724-z ↗
30. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK (1992) A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 86(6 Suppl):III47–III52
31. Liu Y, Acharya G, Lee CH (2011) Effects of dialdehyde starch on calcification of collagen matrix. J Biomed Mater Res A 99(3):485–49210.1002/jbm.a.33209 ↗
32. Mathew S, Varghese S, Rajammal G, Thomas PC (2007) Dipping characteristics of layered silicates-natural rubber latex nanocomposites. J Appl Polym Sci 104(1):58–6510.1002/app.24669 ↗
33. Mellor H, Parker PJ (1998) The extended protein kinase C superfamily. Biochem J 332(Pt 2):281–29210.1042/bj3320281 ↗
34. Minamino T, Kitakaze M (2010) ER stress in cardiovascular disease. J Mol Cell Cardiol 48(6):1105–1110. doi: 10.1016/j.yjmcc.2009.10.02610.1016/j.yjmcc.2009.10.026 ↗
35. Miyauchi K, Kasai T, Yokayama T, Aihara K, Kurata T, Kajimoto K, Okazaki S, Ishiyama H, Daida H (2008) Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model. Circ J 72(5):832–83810.1253/circj.72.832 ↗
36. Morice M-C, Serruys PW, Sousa JE, Fajadet J, Hayashi EB, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773–178010.1056/NEJMoa012843 ↗
37. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315–132310.1056/NEJMoa035071 ↗
38. Munzel T, Feil R, Mulsch A, Lohmann SM, Hofmann F, Walter U (2003) Physiology and pathophysiology of vascular signaling controlled by guanosine 3′,5′-cyclic monophosphate-dependent protein kinase [corrected]. Circulation 108(18):2172–2183. doi: 10.1161/01.CIR.0000094403.78467.C310.1161/01.CIR.0000094403.78467.C3 ↗
39. Nam SH, Nam HY, Joo JR, Baek IS, Park J-S (2007) Curcumin-Loaded PLGA Nanoparticles Coating onto Metal Stent by Electrophoretic Deposition Techniques. Bull Kor Chem Soc 28(3):397–40210.5012/bkcs.2007.28.3.397 ↗
40. Nishizuka Y (1995) Protein kinase C and lipid signaling for sustained cellular responses. Faseb J 9(7):484–49610.1096/fasebj.9.7.7737456 ↗
41. Palaniyandi SS, Sun L, Ferreira JC, Mochly-Rosen D (2009) Protein kinase C in heart failure: a therapeutic target? Cardiovasc Res 82(2):229–239. doi: 10.1093/cvr/cvp00110.1093/cvr/cvp001 ↗
42. Parenteau-Bareil R, Gauvin R, Berthod F (2010) Collagen-based biomaterials for tissue engineering applications. Materials 3(3):1863–188710.3390/ma3031863 ↗
43. Rodriguez AE, Alemparte MR, Vigo CF, Pereira CF, Llaurado C, Russo M, Virmani R, Ambrose JA (2003) Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina single-center study (ORAR Trial). J Invasive Cardiol 15(10):581–584
44. Santoro SA, Cunningham LW (1977) Collagen-mediated platelet aggregation. J Clin Invest 60:1054–106010.1172/JCI108856 ↗
45. Scatena R, Bottoni P, Pontoglio A, Giardina B (2010) Pharmacological modulation of nitric oxide release: new pharmacological perspectives, potential benefits and risks. Curr Med Chem 17(1):61–7310.2174/092986710789957841 ↗
46. Schini-Kerth VB (1999) Vascular biosynthesis of nitric oxide: effect on hemostasis and fibrinolysis. Transfus Clin Biol 6(6):355–36310.1016/S1246-7820(00)88980-6 ↗
47. Serruys PW, Pd Jaegere, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J (1994) A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 331:489–49510.1056/NEJM199408253310801 ↗
48. Singla A, Lee CH (2003) Inhibition of CEM calcification by the sequential pretreatment with ethanol and EDTA. J Biomed Mater Res A 64A(4):706–71310.1002/jbm.a.10375 ↗
49. Spinler SA (2009) Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents. Am J Manag Care 15:S42–S47
50. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy J-J, Park S-J, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370(9591):15–2110.1016/S0140-6736(07)61444-5 ↗
51. Sweeney SE, Firestein GS (2004) Signal transduction in rheumatoid arthritis. Curr Opin Rheumatol 16(3):231–23710.1097/00002281-200405000-00011 ↗
52. Ting J, Lee AS (1988) Human gene encoding the 78,000-dalton glucose-regulated protein and its pseudogene: structure, conservation, and regulation. DNA 7(4):275–28610.1089/dna.1988.7.275 ↗
53. Wang G-R, Zhu Y, Halushka PV, Lincoln TM, Mendelsohn ME (1998) Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci USA 95(9):4888–489310.1073/pnas.95.9.4888 ↗
54. Yamauchi T (2005) Neuronal Ca2+/calmodulin-dependent protein kinase II–discovery, progress in a quarter of a century, and perspective: implication for learning and memory. Biol Pharm Bull 28(8):1342–135410.1248/bpb.28.1342 ↗
55. Yoo JW, Lee JS, Lee CH (2010) Characterization of nitric oxide-releasing microparticles for the mucosal delivery. J Biomed Mater Res A 92(4):1233–1243
56. Yoo J-W, Giri N, Lee CH (2011) pH-sensitive Eudragit nanoparticles for mucosal drug delivery. Int J Pharm 403(1–2):262–26710.1016/j.ijpharm.2010.10.032 ↗